Clinical & Translational Oncology最新文献

{"title":"Stereotactic body radiation therapy (SBRT) practice patterns for spine metastases in Spain: a national survey by the SRS/SBRT SEOR (Spanish Society of Radiation Oncology) Working Group.","authors":"Rafael García, Maria José Pérez-Calatayud, Eva Corrales, Cristina Prieto, Sara Vázquez, Virginia García, Iñigo San Miguel, Carolina de la Pinta, Virginia Morillo, Jose Luis Monroy, Marina Peña, Luis Sopeña, Beatriz Quiles, Héctor Pérez-Montero, Gonzalo Rodríguez, Arturo Navarro, María Veiras, Jesús Blanco, Paula Blasco, Amalia Palacios, Luis Larrea, Javier Aristu, José Expósito, Sergi Benavente, Raquel Ciérvide","doi":"10.1007/s12094-026-04326-4","DOIUrl":"10.1007/s12094-026-04326-4","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the clinical practice in the treatment of spine metastases using stereotactic body radiation therapy (SBRT) among members of the SEOR (Spanish Society of Radiation Oncology) SRS/SBRT Working Goup to gather comprehensive data on clinical protocols, equipment usage, and treatment parameters.</p><p><strong>Materials and methods: </strong>A 31-question electronic survey via Google Forms platform was distributed to members of the Working Group, with responses collected from 24 Spanish institutions, representing 1 per institution. This study aimed to assess demographic profiles, equipment, treatment protocols, immobilization techniques, dose and fractionation schedules, IGRT practices, and prescription criteria for spine SBRT.</p><p><strong>Results: </strong>Most respondents (64.3%) were radiation oncologists with over 10 years of experience. The predominant equipment used was C-LINAC (85.7%). Most institutions (96.4%) had specific protocols for spine metastases management. The Spine Instability Neoplastic Score (SINS) was used by 85.7% of the surveyed for evaluating vertebral stability. According to the number of contiguous spine metastases treated, 81.5% treated up to two. Guidelines from Cox et al. and ESTRO were followed by 96.4% for intact spine metastases, with 81% adhering to Redmond et al. for adjuvant SBRT. Among the 24 surveyed centers, 32.1% used a single dose, 48.1% 2 fractions, 96.3% 3 fractions, and 74.1% 5 fractions. IGRT systems included CBCT (71.4%), X-ray (10.7%), and CBCT and X-ray (25%). The majority of responders (66.7%) indicated coverage of 95% of the PTV with 95-100% of the prescribed dose.</p><p><strong>Conclusion: </strong>This survey highlights significant variability in equipment, protocols, and practices for spine SBRT among Spanish institutions. Standardization of treatment approaches could enhance consistency and oncologic outcomes in spine SBRT.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4885-4891"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action.","authors":"Maria Rosario García-Campelo, Jesús Corral, Fernando Moreno, Andrés Munoz, Jesús M Balea, Begoña Barragán, Jordi Ginés, Fernando Gutiérrez Nicolás, Bruno Sangro, Eva Martín Martin-Sánchez, Marta Trapero-Bertran","doi":"10.1007/s12094-026-04323-7","DOIUrl":"10.1007/s12094-026-04323-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The evaluation of innovative oncology medicines presents significant challenges related to the selection of appropriate clinical endpoints and the sufficiency of evidence, particularly in therapeutic areas, such as immunotherapies, targeted treatments, single-arm trials, and tumor-agnostic therapies. In these contexts, the added value of new treatments is often not adequately captured by traditional clinical trial endpoints, such as overall survival (OS), which remains the gold standard in oncology assessment. This article aims to analyze the main sources of uncertainty in the value assessment of oncology therapies in Spain, with a focus on the limitations of current endpoints and evidence-generation processes, and to provide recommendations for enhancing the recognition and assessment of additional clinical benefit.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A multidisciplinary expert panel composed of twelve professionals, including medical oncologists, hospital pharmacists, health economists, and patient representatives, was convened to identify and discuss key sources of uncertainty in the value assessment of oncology treatments, particularly those related to clinical endpoint selection and evidence generation. The panel participated in three structured plenary sessions. Additional external experts were engaged to provide complementary input in areas, such as tumor-specific characteristics and statistical methodology. Consensus statements were developed through an iterative process of discussion, critical appraisal, and refinement across and between sessions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The expert panel issued twelve recommendations to improve value assessment in oncology. These include tailoring clinical endpoints to treatment type, tumor characteristics, and stage; complementing overall survival with milestone analysis and quality-of-life measures; and standardizing real-world evidence collection across the healthcare system. The panel advocated for a national portfolio of prioritized endpoints, appropriate statistical methods by context, and the conditional use of early-phase data for decision-making. Additional recommendations addressed the use of synthetic control arms, flexible reimbursement models, advanced analytics (e.g., AI and Big Data), evaluator expertise, and the promotion of stakeholder training and transparency.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Addressing the challenges of clinical endpoint selection and evidence generation is essential to reduce uncertainty in the value assessment of innovative oncology treatments. The twelve expert recommendations outlined in this study provide a structured roadmap to improve methodological consistency, enhance the relevance and robustness of clinical and real-world data, and promote a more adaptive and transparent evaluation framework. These proposals aim to support more evidence-based, equitable, and sustainable decision-making within the Spanish healthcare syst","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4947-4957"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.","authors":"JiaJu Xu, ChunXiao Ni, Lidong Qin, Ping Wang, JiaJu Xu","doi":"10.1007/s12094-026-04330-8","DOIUrl":"10.1007/s12094-026-04330-8","url":null,"abstract":"<p><p>The emergence of immune checkpoint inhibitors (ICIs) has ushered in a new era of tumor immunotherapy. These agents function by specifically binding to immune checkpoints, blocking the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway, and inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) signaling. This action suppresses the negative immune regulatory mechanisms of tumors, prevents immune escape, and activates T cells. Consequently, ICI treatment restores the cytotoxic activity of effector T cells against tumor cells, exerts antitumor effects, delays tumor progression, and ultimately prolongs patient survival while improving clinical outcomes. ICIs have now been approved for first-line or second-line treatment of various malignancies. However, in some patients, immunotherapy not only fails to confer a survival benefit but may also lead to rapid tumor progression shortly after treatment initiation, a phenomenon clinically known as hyperprogressive disease (HPD). Currently, research on the underlying mechanisms, predictive biomarkers, and effective therapeutic strategies for HPD remains limited. This article comprehensively reviews the definition, differential diagnosis, pathogenesis, and potential predictive markers of HPD, including inflammatory and immune-related biomarkers, clinical factors, and tumor-related markers. The objective of this study is to provide a theoretical foundation and practical guidance for the early identification of HPD and the optimization of clinical treatment strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4419-4460"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Textbook outcome in ovarian cancer with peritoneal carcinomatosis: a systematic review.","authors":"Silvia Carbonell-Morote, Pedro Antonio Cascales-Campos, Álvaro Arjona-Sánchez, Juan Jesús Rubio, Celia Villodre, Francisco Javier Lacueva, José Manuel Ramia","doi":"10.1007/s12094-026-04378-6","DOIUrl":"10.1007/s12094-026-04378-6","url":null,"abstract":"<p><strong>Objective: </strong>Textbook Outcome (TO) has emerged as a composite quality metric in oncologic surgery, but its role in ovarian cancer-related peritoneal carcinomatosis remains unclear. This systematic review aimed to evaluate the definitions, achievement rates, and clinical relevance of TO in patients undergoing cytoreductive surgery for ovarian cancer with peritoneal carcinomatosis.</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed, Embase, Scopus, and Web of Science following PRISMA 2020 guidelines. Studies evaluating composite outcomes or TO in ovarian cancer patients with peritoneal carcinomatosis were included. Data on study characteristics, TO definitions, achievement rates, and associations with oncologic outcomes were extracted. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS).</p><p><strong>Results: </strong>From 47 identified records, three observational studies met the inclusion criteria. Definitions of TO varied across studies but consistently included complete cytoreduction as a core component. TO achievement rates ranged from 20.5% to 55.9%. Two studies demonstrated a significant association between TO achievement and improved overall survival, while one population-based study highlighted substantial inter-hospital variability in TO rates. All included studies were rated as having good methodological quality according to the Newcastle-Ottawa Scale (NOS).</p><p><strong>Conclusions: </strong>Despite heterogeneity in definitions, TO appears to be a promising composite quality indicator, although current evidence remains limited and should be interpreted with caution in ovarian cancer surgery with peritoneal carcinomatosis and is consistently associated with improved oncologic outcomes. These findings support the need for an internationally standardized definition of TO to facilitate benchmarking, quality improvement, and future prospective research in this complex clinical setting.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4706-4713"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147788134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long noncoding RNAs in female malignancies: critical review of molecular mechanisms, clinical gaps, and therapeutic perspectives.","authors":"Xia Liu, Xia Li, Shaofeng Zou, Li Hao, Xiuyang Xie","doi":"10.1007/s12094-026-04386-6","DOIUrl":"10.1007/s12094-026-04386-6","url":null,"abstract":"<p><p>The most frequent malignancies affecting women are cervical, breast, ovarian, and uterine cancers, which account for the majority of cancer-related deaths among women in both developed and developing nations. These cancers exhibit high aggressiveness due to their invasive and metastatic potential. Consequently, it is crucial to investigate the mechanisms underlying female cancers. Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that regulate gene expression without encoding proteins. LncRNAs modulate gene expression by interacting with proteins, modifying transcription, and influencing cellular pathways, thereby regulating a variety of biological processes. It has been recognized that lncRNAs play a major role in the initiation and development of several human cancers, including lung, colorectal, prostate, and breast cancers, as well as other pathological processes that significantly impact the prognosis and survival of cancer patients. Furthermore, the distinct expression patterns of lncRNAs across numerous cancer types significantly increase their potential as biomarkers and therapeutic targets. This review explores the role of lncRNAs in female malignancies to provide a solid foundation for future research on the prevention and treatment of female-oriented cancers. The potential significance of lncRNAs as biomarkers and targets for medical therapies is also discussed.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4560-4574"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-1α (IL-1α) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers.","authors":"Ke Ling, Guangfei Xie, Ze Chen, Mingxu Da, Zhisheng Qiu","doi":"10.1007/s12094-026-04325-5","DOIUrl":"10.1007/s12094-026-04325-5","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a 5-year survival rate of only 12%, driven by late diagnosis, rapid metastasis, and an immunosuppressive tumor microenvironment (TME). Current therapies, including chemotherapy and immune checkpoint blockade, show limited efficacy due to the \"cold\" TME. Interleukin-1α (IL-1α) plays a central role in PDAC progression. TCGA (n = 178) and ICGC (n = 267) analyses reveal that high IL1A expression independently predicts poor overall survival (HR = 1.99, 95% CI 1.01-3.93) and progression-free survival (HR = 3.11, 95% CI 1.24-7.80). As a biomarker, IL-1α outperforms traditional CA19-9 for risk stratification and treatment selection. Its detection in serum and exosomes supports potential applications in liquid biopsy for early detection. Therapeutically, IL-1α blockers using agents such as anakinra, canakinumab, and nadunolimab show synergy with immune checkpoint inhibitors and chemotherapy. This combination has been evaluated in preclinical models and early-phase clinical trials. It achieves disease control rates of up to 62% and median progression-free survival of up to 6.8 months, while also reducing fibrosis and enhancing antitumor immunity. This review synthesizes the critical role of interleukin-1α (IL-1α) in PDAC pathogenesis and its potential implications for immunotherapy and molecular biomarker development. IL-1α is highly expressed in PDAC tumor cells and tumor-associated macrophages (TAMs). It activates the NF-κB and MAPK pathways, thereby promoting epithelial-mesenchymal transition (EMT), stromal fibrosis, and immunosuppression. This includes the recruitment of neutrophils and myeloid-derived suppressor cells (MDSCs), which collectively maintain an immunosuppressive ('cold') tumor microenvironment (TME) and contribute to therapeutic resistance. Future multi-omics stratification, targeted delivery systems, and rational combination strategies hold promise for improving PDAC outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4297-4307"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The intersection of colorectal cancer and cardiovascular disease: shared mechanisms and clinical implications.","authors":"Shuzhen Wu, Luyao Yu, Meitong Liu, Bo Dong","doi":"10.1007/s12094-026-04367-9","DOIUrl":"10.1007/s12094-026-04367-9","url":null,"abstract":"<p><p>Colorectal cancer (CRC) and cardiovascular disease (CVD) are major contributors to the global disease burden, with CRC as the third most common malignancy and second leading cause of cancer-related death, and CVD as the top killer among non-communicable diseases. The growing ageing population has driven a continuous rise in CRC-CVD comorbidity. Treatment-related cardiovascular toxicity, shared pathophysiological links, and the prognostic impact of comorbidity have made this interdisciplinary field a critical focus in cardio-oncology. This review addresses core scientific questions at the CRC-CVD intersection, including their shared risk factors and pathological mechanisms (metabolic syndrome, chronic inflammation, oxidative stress, gut microbiota dysbiosis, etc.), epidemiological and molecular associations between CRC and major CVD subtypes, as well as cardiovascular toxicity mechanisms, monitoring, and intervention strategies for CRC therapies (chemotherapy, targeted therapy, immunotherapy). Beneficial lifestyle modifications and cross-effective medications, together with multidisciplinary team (MDT) collaboration, hold great value for comorbidity management. Current studies have confirmed their epidemiological and partial mechanistic links, but key gaps remain: unclear core molecular regulatory networks, insufficient gut microbiota-cardiovascular-tumor axis research, lack of personalized risk prediction models, limited long-term cardiovascular data for novel anticancer drugs, and absent standardized precision prevention protocols. Future multi-omics studies, large-scale clinical trials, and real-world data research will help clarify shared targets, build risk models, and formulate interdisciplinary management guidelines to improve outcomes of CRC-CVD comorbidity patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4346-4358"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.","authors":"Tongtong Chu, Xiuxi Li, Lijuan Shan, Chunshan Zhao","doi":"10.1007/s12094-026-04372-y","DOIUrl":"10.1007/s12094-026-04372-y","url":null,"abstract":"<p><strong>Background: </strong>The systemic inflammation response index (SIRI) is an emerging inflammation-immune indicator calculated from counts of neutrophils, monocytes, and lymphocytes. The potential prognostic value of SIRI in various tumors has been reported in several studies. However, updated and comprehensive evidence regarding its prognostic value in lung cancer (LC) remains insufficient. This study, through a systematic review and meta-analysis, intends to comprehensively analyze the relationship of SIRI with overall survival (OS) and progression-free survival (PFS) among individuals experiencing LC.</p><p><strong>Methods: </strong>Cochrane Library, Web of Science, Embase, and PubMed were systematically searched from the commencement of the databases to October 2025. Cohort studies reporting the relation of SIRI with OS or PFS were included. Hazard ratios (HRs) alongside their 95% confidence intervals (CIs) were obtained, and a random-effects model was employed for data synthesis. Subgroup analysis, sensitivity analysis, and assessment of publication bias were conducted to evaluate the robustness of the findings.</p><p><strong>Results: </strong>In total, 27 studies involving 6195 patients with LC were incorporated into this meta-analysis, which revealed that high SIRI levels were significantly associated with poorer OS (HR = 1.83, 95% CI 1.58-2.13) and PFS (HR = 1.53, 95% CI 1.31-1.79). Differences in age, region, and cutoff value for SIRI were identified as the primary sources of heterogeneity. The sensitivity analysis indicated stable results, while the Egger's test demonstrated publication bias.</p><p><strong>Conclusion: </strong>A higher SIRI level is significantly associated with adverse survival outcomes among individuals suffering from LC. As a simple and low-cost hematological marker, SIRI is potentially applied in the risk stratification and prognosis assessment of LC. In the future, prospective studies based on multicenter data and with a larger sample size, and a unified cutoff standard for SIRI are warranted to further corroborate the clinical utility of SIRI.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4643-4656"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Informational and structural barriers to exercise oncology care in Spain: development of the MOVE-Onco questionnaire and preliminary findings.","authors":"Almudena Martínez Sánchez, Maria Mendoza-Muñoz, Francisco J Dominguez-Muñoz, Candela Guerrero-Torrico, Narcis Gusi, Jeyanthi Subburaj, Santos Villafaina","doi":"10.1007/s12094-026-04375-9","DOIUrl":"10.1007/s12094-026-04375-9","url":null,"abstract":"<p><strong>Purpose: </strong>Exercise is recommended as a core component of supportive cancer care; however, its implementation remains inconsistent. Beyond individual motivation, social and healthcare system factors may shape access to structured exercise programs. This study aimed to develop and content-validate the Motivators, Obstacles, Values, and Exercise in Oncology (MOVE-Onco) questionnaire and to provide preliminary evidence on informational and structural barriers to exercise among oncology patients in Spain.</p><p><strong>Methods: </strong>A multi-phase study was conducted including: (1) qualitative item generation through patient interviews and cognitive debriefing; (2) a two-round Delphi process with a multidisciplinary expert panel (N = 16) using a ≥ 75% consensus criterion; and (3) a pilot cross-sectional application in 53 oncology patients to assess internal consistency and describe perceived barriers, facilitators, knowledge, and preferences.</p><p><strong>Results: </strong>Content validity was achieved with ≥ 75% expert agreement in the final Delphi round. Internal consistency was excellent for the Barriers scale (α = 0.91) and good for the Facilitators scale (α = 0.85). Although most participants believed exercise improves health outcomes (98.1%) and expressed interest in structured programs (86.9%), 67.9% reported not receiving professional exercise guidance and 94.3% were unaware of specialized oncology exercise resources. Informational barriers were more frequently endorsed than physical or psychological limitations in this pilot sample.</p><p><strong>Conclusions: </strong>The MOVE-Onco questionnaire demonstrates preliminary content validity and internal consistency in a Spanish oncology context. Pilot findings suggest that limited professional guidance and low awareness of available resources, rather than lack of patient motivation, may constitute key barriers to exercise engagement. These results highlight potential structural gaps in supportive cancer care delivery. However, these findings should be interpreted cautiously and require confirmation in larger studies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4958-4971"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red cell distribution width as a prognostic predictor for colorectal cancer: a meta-analysis.","authors":"Ruixue Fan, Yijiang Zhang, Junwei Feng","doi":"10.1007/s12094-026-04347-z","DOIUrl":"10.1007/s12094-026-04347-z","url":null,"abstract":"<p><strong>Purpose: </strong>Red cell distribution width (RDW) is a simple, low-cost hematological indicator that reflects systemic inflammation and nutritional status. Nevertheless, its prognostic value in colorectal cancer (CRC) remains uncertain. The current meta-analysis aimed to determine the predictive value of preoperative RDW levels for postoperative survival outcomes in individuals with CRC.</p><p><strong>Methods: </strong>Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, the Cochrane Library, Embase, PubMed, and Web of Science were searched for studies investigating the correlation of RDW with survival outcomes in CRC. Meta-analysis was executed using Stata 15. Subgroup analyses investigated sources of heterogeneity.</p><p><strong>Results: </strong>The analysis incorporated 16 studies, involving 20,500 individuals with CRC. Pooled results indicated that an elevated preoperative RDW-coefficient of variation (CV) was related to poorer overall survival (OS) (multivariable-adjusted pooled hazard ratio [HR] = 1.27, 95% confidence interval [CI] 1.00-1.60, I² = 68%). Analysis based on RDW-standard deviation (SD) revealed stronger relevance (multivariable-adjusted HR = 1.89, 95% CI 1.31-2.72). Furthermore, a high preoperative RDW-CV independently correlated with inferior disease-free survival (multivariable-adjusted HR = 1.16, 95% CI 1.01-1.33, I² = 54%). Subgroup analysis indicated a more consistent association of RDW with survival outcomes among subjects who did not receive neoadjuvant therapy (OS: HR = 1.64, 95% CI 1.15-2.34).</p><p><strong>Conclusion: </strong>An increased preoperative RDW was independently linked to adverse postoperative survival outcomes in individuals with CRC. RDW-SD may offer superior predictive capability. As an accessible and inexpensive biomarker, RDW holds potential clinical utility for postoperative risk stratification. Nonetheless, existing research is predominantly retrospective. Standardized thresholds and measurement timing for RDW are lacking. Thus, future prospective multicenter studies are required for standardized validation.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4767-4780"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}